Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 3,084 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Guideline Clear all

Conditions: Chronic Kidney Diseases, Acute Coronary Syndrome
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina • Dallas, Texas

Conditions: Diabetes, Hypertension, Depression, Osteoarthritis, Asthma, Pain, Heart Failure
Interventions: Continuing Medical Education, Quality IQ Patient Simulations; Other
Lead sponsor: Qure Healthcare, LLC; Industry
Eligibility: Not listed
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiorespiratory and Vascular Dysfunction, Obstructive Airway Disease
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Depression in Remission, Depressive Symptoms, Depression
Interventions: Mindfulness-Based Cognitive Therapy, Wellness for Wellbeing; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
Interventions: Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Heart Failure, Heart Failure, Systolic
Interventions: Pharmacist/Cardiologist Virtual Team Digital Consultation; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Head and Neck Neoplasms
Interventions: Registry; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
Interventions: Megestrol Acetate, iKanEat Behavioral Intervention; Drug · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 9 Months to 108 Months
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 8
States / cities: San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more

Conditions: Quality Improvement, Pharmacotherapy, Heart Failure
Interventions: Education Only, Education and Feedback (E+F), Primary Care Referral Nudges; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Sedentary Behavior, Cognitive Impairment
Interventions: Ecological Momentary Intervention; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 55 Years to 89 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Community Acquired Pneumonia (CAP), Sinusitis, Strep Pharyngitis, Acute Otitis Media (AOM)
Interventions: Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support, Live, hybrid in-person and online educational sessions; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 12 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Optimized Treatment (OPT); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more

Conditions: Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease Patients, Neuromuscular Disease, Respiratory Insufficiency, Respiratory Insufficiency Requiring Mechanical Ventilation, Positive Pressure Ventilation, Non-invasive Ventilation, Non-invasive Ventilation Support, Non-invasive Ventilatory Support
Interventions: Non-invasive ventilation; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania • Philadelphi, Pennsylvania

Conditions: Cerebral Palsy, Central Nervous System Diseases, Brain Damage, Chronic
Interventions: Power training combined with interval treadmill training, Strength training combined with traditional treadmill training; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 10 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: New Orleans, Louisiana • Seattle, Washington

Conditions: Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction, Stress, Chronic Lung Disease, Growth Acceleration, Adverse Event
Interventions: NICU Dashboard; Device
Lead sponsor: Philips Healthcare; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acute Stroke, Brain Ischemia, Ischemic Stroke
Interventions: Endovascular Treatment (EVT); Procedure
Lead sponsor: Firas Al-Ali; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Atlanta, Georgia • New York, New York • Rochester, New York + 3 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Best Practice, Internet-Based Intervention, Questionnaire Administration, Survey Administration; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Sleep Disordered Breathing (SDB), Sleep Apnea
Interventions: SSAM, Polysomnography, EnsoSleep; Device · Diagnostic Test
Lead sponsor: Pathway Medtech, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Burlingame, California • Irvine, California • La Jolla, California

Conditions: Tobacco Use Cessation, Tobacco Smoking
Interventions: Tobacco quitline EHR referral, Tobacco quitline Fax referral; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 14,930 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Locally Advanced Rectal Cancer
Interventions: Intensity-modulated radiation therapy, 5-fluorouracil, Leucovorin, Oxaliplatin, Capecitabine, Accelerated Radiation Therapy, Irinotecan; Radiation · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infant, Obesity
Interventions: Child Safety Insights, Parenting Insights; Behavioral
Lead sponsor: Ian M. Paul, MD; Other
Eligibility: 1 Day and older
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 2
States / cities: Hershey, Pennsylvania • State College, Pennsylvania

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy; Procedure
Lead sponsor: NRG Oncology; Other
Eligibility: 45 Years to 70 Years
Enrollment: 9,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2065
U.S. locations: 484
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 328 more

Conditions: Pregnancy, Overweight and Obesity
Interventions: Exercise Modes; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Greenville, North Carolina

Search by objective public record fields.

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

Quality IQ Patient Simulation Physician Practice Measurement and Engagement

World Trade Center Particulate Matter Induced Cardiorespiratory and Vascular Dysfunction: a MultiOmic Approach (CaRVD)

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Mood and Thought Process Study

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Pharmacist-Assisted Titration of Rx to Implement Optimal Medical Therapy for Heart Failure

Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

Veterans Affairs Pharmacist Heart Failure Medication Titration Project 2

A Physical Activity Program to Disrupt Sedentary Time in Older Latinos

Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)

Power Training Combined With Interval Treadmill Training

Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO

The Capillary Index Score Trial

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Detection of Sleep Stages and Arousals Using Neural Network Classifiers

EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Pregnancy Exercise Mode Effect on Childhood Obesity